Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 10/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CASP9 | P55211 | 1/20 | 0.38 |
| ▸ | VHL | P40337 | 2/20 | 0.37 |
| ▸ | ELOC | Q15369 | 2/20 | 0.37 |
| ▸ | ELOB | Q15370 | 2/20 | 0.37 |
| ▸ | BIRC3 | Q13489 | 4/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10284013 | 1.00 | XIAP (0.41) | XIAPPOLBCASP9VHLELOC | |
| SCHEMBL2632117 | 0.94 | XIAP (0.40) | XIAPPOLBCASP9BIRC3BIRC2 | |
| SCHEMBL2632212 | 0.92 | XIAP (0.47) | XIAPCASP9BIRC3BIRC2 | |
| SCHEMBL2114994 | 0.92 | XIAP (0.47) | XIAPCASP9BIRC3BIRC2 | |
| SCHEMBL15312597 | 0.89 | GLA (0.42) | XIAPPOLBCASP9BIRC3BIRC2 | |
| SCHEMBL13049925 | 0.89 | GLA (0.42) | XIAPPOLBCASP9BIRC3BIRC2 | |
| SCHEMBL15095357 | 0.85 | XIAP (0.42) | XIAPPOLBCASP9BIRC3BIRC2 | |
| SCHEMBL8513783 | 0.83 | BIRC2 (0.43) | XIAPPOLBCASP9BIRC3BIRC2 | |
| SCHEMBL9613410 | 0.83 | BIRC2 (0.43) | XIAPPOLBCASP9BIRC3BIRC2 | |
| SCHEMBL2631853 | 0.82 | XIAP (0.41) | XIAPCASP9BIRC3BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2434889-B1 | IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | XIAP 1/4885POLB 3851/4885CASP9 63/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | XIAP 1/4885POLB 3851/4885CASP9 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.